You are here

Lumoxiti Injection Approved for Hairy Cell Leukemia

Cleared for Adults with Relapsed or Refractory Disease

Lumoxiti injection (moxetumomab pasudotox-tdfk, Astra Zeneca) has been approved to treat certain instances of relapsed or refractory "hairy cell" leukemia (HCL) in adults. The new drug is the latest addition to a novel class of drugs called CD22-directed cytotoxins to treat HCL, the FDA announced. The drug was approved for adults who have had at least two prior therapies for the disease.

Lumoxiti was evaluated in a clinical study of 80 people who had been treated previously for HCL. The most common side effects included injection-related reactions, swelling, nausea, fatigue, headache, fever, constipation, anemia, and diarrhea.

The drug's label includes a boxed warning of increased risk for capillary leak syndrome, and also notes an increased risk of hemolytic uremic syndrome. Breastfeeding women should not take the drug.

Source: U.S. News & World Report, September 13, 2018

More Headlines

Disease Occurs in 1 in 5,000 Male Births in the U.S.
Non-Invasive Therapy for Patients Who are Nonresponsive to Antidepressants
Vials Being Rationed, Only One Manufacturer
Several Health Insurers Now Consider DBS Therapy for Epilepsy a Covered Indication
Drug Has Potential Role In Oxidative Stress, Inflammation, and Neurodegeneration
OCA Meets Primary Endpoint of Improvement in Liver Fibrosis
Scan Could Improve Understanding of Dopamine Function in Schizophrenia
Test Determines Severity of Pain, Helps Physicians Select Best Options